By correcting CFTR dysfunction and improving both mucociliary clearance and “tightening” inflammatory signaling across cellular phospholipid membranes, CFTR modulator therapy may reduce the inflammatory burden of typical CF pathogens, creating a new airway microbiome [126]. The gene discussed is CFTR; the disease is cystic fibrosis.